The recommendation makes a second drug available in England for treating transthyretin amyloidosis with cardiomyopathy.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Bayer's HER2 inhibitor Hyrnuo (sevabertinib) for patients with advanced or metastatic non-squamous non-small ...

NEW YORK – Nuvalent is angling for US approval in 2026 of its ALK inhibitor neladalkib for previously treated patients with ALK-positive non-small cell lung cancer after a pivotal Phase II trial ...

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.